+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Tuberculosis (TB)

  • ID: 4846148
  • Report
  • October 2020
  • Region: Global
  • 41 Pages
  • Datamonitor Healthcare

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Evotec
  • GlaxoSmithKline
  • Sanofi
  • MORE
This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.

Key Takeaways

The publisher estimates that in 2018, there were 13.9 million incident cases of tuberculosis (TB) worldwide, and forecasts that number to increase to 15.3 million incident cases by 2027.

Approved drugs in the TB space focus on a variety of targets. The majority of these drugs are administered via the oral route, with the remainder being topical and intravenous formulations.

The majority of industry-sponsored drugs in active clinical development for TB are in Phase II. Therapies in mid-to-late-stage development for TB focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being tested in intramuscular and intradermal formulations.

The only high-impact upcoming event for drugs in the TB space is topline Phase II trial results for GSK3036656. The overall likelihood of approval of a Phase I antibacterial, mycobacterial, or fungal asset is 24.6%, and the average probability a drug advances from Phase III is 62.9%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.1 years in the overall infectious disease space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for TB have been in the early and midphases of development, with 74% of trials in Phase I-II, and only 26% in Phase III-IV.

South Africa has a substantial lead in the number of TB clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.

Clinical trial activity in the TB space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for TB, with 17 trials.

GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for TB.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Evotec
  • GlaxoSmithKline
  • Sanofi
  • MORE
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
  • Disease definition
  • Patient subtypes
  • Symptoms
  • Risk factors
  • Diagnosis
TREATMENT
  • Anti-TB drugs
  • Surgery
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • Pretomanid for TB (June 6, 2019)
  • Pretomanid for TB (June 4, 2019)
  • Pretomanid for TB (April 18, 2019)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • The FDA’s Latest Nitrosamine Decision Weighs Tuberculosis Versus Cancer Risk
  • Hope For Price Flexibility After India Pretomanid Go-Ahead
  • Pediatric Approvals In TB, Bladder Dysfunction, And Atopic Dermatitis
  • Mylan Gets Expert Panel Go-Ahead For Pretomanid In India
  • Global Approvals Snapshot: November 2019
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • Pfizer Deal Covers Sutezolid For TB
  • Deals Shaping The Medical Industry, December 2019
  • Shionogi, Hsiri Expand Mycobacterial R&D Pact
CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
BIBLIOGRAPHY
  • Prescription information
APPENDIX

List of Figures
  • Figure 1: Global trends in incident cases of tuberculosis, 2018-27
  • Figure 2: Overview of pipeline drugs for tuberculosis in the US
  • Figure 3: Pipeline drugs for tuberculosis, by company
  • Figure 4: Pipeline drugs for tuberculosis, by drug type
  • Figure 5: Pipeline drugs for tuberculosis, by classification
  • Figure 6: Key upcoming events in tuberculosis
  • Figure 7: Probability of success in the antibacterial, mycobacterial, or fungal pipeline
  • Figure 8: Clinical trials in tuberculosis
  • Figure 9: Top 10 drugs for clinical trials in tuberculosis
  • Figure 10: Top 10 companies for clinical trials in tuberculosis
  • Figure 11: Trial locations in tuberculosis
  • Figure 12: Tuberculosis trials status
  • Figure 13: Tuberculosis trials sponsors, by phase
List of Tables
  • Table 1: Global incident cases of tuberculosis, 2018-27
  • Table 2: Global incident cases of tuberculosis with HIV, 2018
  • Table 3: Global incident cases of MDR/RR tuberculosis, 2018
  • Table 4: Marketed drugs for tuberculosis
  • Table 5: Pipeline drugs for tuberculosis in the US
  • Table 6: Pretomanid for TB (June 6, 2019)
  • Table 7: Pretomanid for TB (June 4, 2019)
  • Table 8: Pretomanid for TB (April 18, 2019)
Note: Product cover images may vary from those shown
  • GlaxoSmithKline
  • Sanofi
  • Evotec
Note: Product cover images may vary from those shown
Adroll
adroll